Verona Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Verona Pharma has a total shareholder equity of $130.5M and total debt of $120.0M, which brings its debt-to-equity ratio to 92%. Its total assets and total liabilities are $381.8M and $251.3M respectively.
Key information
92.0%
Debt to equity ratio
US$120.01m
Debt
| Interest coverage ratio | n/a |
| Cash | US$336.04m |
| Equity | US$130.49m |
| Total liabilities | US$251.33m |
| Total assets | US$381.82m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: I9SA's short term assets ($364.3M) exceed its short term liabilities ($28.0M).
Long Term Liabilities: I9SA's short term assets ($364.3M) exceed its long term liabilities ($223.4M).
Debt to Equity History and Analysis
Debt Level: I9SA has more cash than its total debt.
Reducing Debt: I9SA's debt to equity ratio has increased from 0% to 92% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: I9SA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: I9SA has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 13.6% each year.